A Medicare Advantage insurer that runs on software - and finally on profit.
A doctor opens a laptop before a 78-year-old patient sits down. On the screen is a tidy brief: likely undiagnosed conditions, a medication that may be doing more harm than good, a lab test that is overdue. The doctor did not assemble any of this. A piece of software called Clover Assistant did - by reading millions of data points the patient never knew existed.
That moment is Clover Health in 2026. Not a clinic, not an app, but an insurance company that behaves like a tech company and a tech company that happens to sell insurance. It covers roughly 153,000 seniors on Medicare Advantage and, after years of being the cautionary tale of the SPAC era, it has done the most unfashionable thing a healthcare startup can do: it started making money.
American healthcare is very good at treating disease once it has become a crisis and surprisingly bad at catching it early. For seniors on Medicare, the math is brutal: a chronic condition spotted late costs more, hurts more, and tends to drag a string of other conditions behind it. The information needed to intervene early usually exists - scattered across electronic health records, pharmacies, labs, and a doctor's memory - but almost never in one place at the right moment.
Clover's founders looked at this and saw a data problem wearing a healthcare costume. Physicians were not failing for lack of skill. They were failing for lack of a complete picture at the exact second a decision gets made.
Fig. 1 - The most radical idea in this entire profile is also the most boring: put the right information on the screen before the patient finishes saying hello.
Clover Health was founded in 2013 by Vivek Garipalli and Kris Gale. Garipalli had already run a hospital chain in New Jersey, which gave him an uncomfortably close view of how the money actually moves - and who pays when care arrives too late. Gale brought the engineering instinct that the fix would be software, not more paperwork.
Their bet was contrarian. Instead of competing on marketing or network size alone, they would compete on data and machine learning - lowering medical costs by helping doctors act earlier. It was the kind of bet that sounds obvious in a deck and is agonizing to execute in a regulated, low-margin business. Investors including GV, Sequoia and Greenoaks signed on across roughly $925M in private funding.
Today Vivek Garipalli serves as Executive Chairman, and Andrew Toy - the technologist who championed Clover Assistant - runs the company as CEO.
Clover Assistant is the company's nervous system. It aggregates data from EHRs, pharmacies, labs and socioeconomic sources, then uses machine learning to surface personalized, point-of-care recommendations - suggested diagnoses, medications, dosages, tests and referrals. Andrew Toy calls it a "digital on-ramp for value-based care." In plainer English: it is a cheat sheet for doctors, except the cheating is allowed and the patient benefits.
AI software that hands physicians a complete, personalized brief at the moment of care.
Wide-network plans with low out-of-pocket costs and rich supplemental benefits.
The subsidiary that licenses Clover's platform to other providers and payers.
In-home primary and preventive care for higher-need members.
Fig. 2 - Four products, one idea: see it sooner, spend less later. Everything else is implementation detail.
For members, the pitch is refreshingly concrete: a Medicare Advantage PPO with a broad network, low out-of-pocket costs, and supplemental benefits spanning dental, vision, hearing, OTC allowances and fitness. For physicians, it is a free tool that makes their job easier. For Clover, every early catch is a cost it does not have to pay later. The incentives, for once, point the same direction.
For a long time, Clover's story was told in stock-price obituaries. The shares went from a pre-merger $10 to an all-time high near $28.85 and then to roughly $4 - a SPAC arc that launched a thousand smug tweets. But the operating business kept compounding while the market looked away.
Growth is one thing; growth that pays for itself is another. Membership climbed 38% in 2025 and another 53% during the 2026 enrollment window, and yet the company guided to its first full-year GAAP net income in 2026 on revenue of $2.81B-$2.92B. In an industry where scale often means scaling losses, that combination is the whole argument.
Fig. 3 - A chart of members going up and to the right. The interesting part is the part you can't draw: the costs that didn't happen.
Clover's ambition has outgrown its own insurance plan. Through Counterpart Health, it now licenses the underlying platform to other providers and payers - which means a competitor's doctor could one day be making better decisions because of Clover's software. The company has been candid that this is early and not yet a major economic contributor, which is a more honest framing than most companies manage about their shiniest new thing.
The stated mission is unfussy: make great healthcare affordable and accessible, especially for older adults. CEO Andrew Toy has testified to Congress on advancing healthcare through AI and has said plainly that he wants to "double down on health equity." For Clover, equity is not only a value - it is the addressable market.
Clover competes with giants - UnitedHealth's Optum, Humana, CVS/Aetna - and a pack of insurgents like Alignment, Devoted and Oscar. It will not out-spend any of them. Its bet is that in Medicare, over a long enough horizon, the company with the best data and the cleanest feedback loop simply wins more often than it loses.
Back to that doctor and that 78-year-old. A decade ago, the visit starts cold: a rushed history, a hunch, a prescription that may or may not interact with three others. Now the screen has already done the remembering. The condition gets caught this year instead of next. The hospital stay that would have happened doesn't. That is the entire company, compressed into fifteen minutes - quiet, unglamorous, and finally profitable.